| Literature DB >> 23409777 |
Urs Wenger1, Thomas A Neff, Christian E Oberkofler, Manuel Zimmermann, Paul A Stehberger, Marcel Scherrer, Reto A Schuepbach, Silvia R Cottini, Peter Steiger, Markus Béchir.
Abstract
BACKGROUND: Renal failure with following continuous renal replacement therapy is a major clinical problem in liver transplant recipients, with reported incidences of 3% to 20%. Little is known about the significance of postoperative acute renal failure or acute-on-chronic renal failure to postoperative outcome in liver transplant recipients.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23409777 PMCID: PMC3582487 DOI: 10.1186/1471-2369-14-37
Source DB: PubMed Journal: BMC Nephrol ISSN: 1471-2369 Impact factor: 2.388
Baseline characteristics (n=135)
| Age (yrs.) | 51.1±12.0 (18.0–70.5) |
| Weight (kg) | 77.6±16.0 (43.0–136.0) |
| Height (m) | 1.73±0.10 (1.50–1.95) |
| BMI (kg/m2) | 25.8±4.3 (16.0–36.0) |
| Creatinine (μmol/l) | 99±44 (40–306) |
| Hematocrit (%) | 32.4±6.6 (19.3–49.6) |
| Platelets (103/μl) | 103±60 (22–285) |
Data expressed as mean ± SD (range).
Underlying liver diseases (n=135)
| HCV liver cirrhosis overall | 51 (37.7%) |
| HCV liver cirrhosis + HCC | 18 (12.8%) |
| HBV liver cirrhosis overall | 13 (9.6%) |
| HBV liver cirrhosis +HCC | 6 (4.4%) |
| HCC overall | 37 (27.4%) |
| Alcoholic liver cirrhosis overall | 24 (17.7%) |
| Alcoholic liver cirrhosis + HCC | 1 (0.7%) |
| PSC | 5 (3.7%) |
| PBC | 4 (2.9%) |
| Wilson’s disease | 4 (2.9%) |
| Cryptogenic liver cirrhosis | 2 (1.5%) |
| Amyloidosis | 3 (2.2%) |
| Budd chiari syndrome | 2 (1.5%) |
| Alpha-1-antitrypsin deficiency | 1 (0.7%) |
| AIH liver cirrhosis | 1 (0.7%) |
| Osler’s disease | 1 (0.7%) |
| Other | 2 (1.5%) |
| Acute liver failure | 11 (8.1%) |
HCV indicates hepatitis C virus, HBV hepatitis B virus, HCC hepatocellular carcinoma, PSC primary sclerosing cholangitis, PBC primary biliary cirrhosis and AIH autoimmune hepatitis, respectively.
Figure 1Kaplan Meier curve of the 4 groups: There were significant different survival rates. The lowest cumulative survival shows group 1, with preoperative normal kidney function and postoperative renal replacement therapy (p<.0001, log rank test)
Mortality
| ICU (%) | 20.0 | 2.4 | 0 | 0 | 0.008 |
| Hospital (%) | 26.7 | 2.4 | 10.0 | 0 | 0.002 |
| Overall (%) | 46.7 | 12.9 | 20.0 | 8.0 | 0.015 |
Comparison with Chi-Test.
Group 1: Calculated Cockcroft formula ≥ 60 ml/min with postoperative RRT.
Group 2: Calculated Cockcroft formula ≥ 60 ml/min without postoperative RRT.
Group 3: Calculated Cockcroft formula ≤ 60 ml/min with postoperative RRT.
Group 4: Calculated Cockcroft formula ≤ 60 ml/min without postoperative RRT.
Patients with normal baseline creatinine clearance (> 60 ml/min)
| Gender (m/f) | 2/13 | 24/61 | 0.22 |
| Age (yrs.) | 58 (30–65) | 52 (16–69) | 0.39 |
| BMI (kg/m2) | 26.7 (23.2–36.0) | 24.8 (16.0–36.2) | 0.05 |
| Hematocrit before TPL (%) | 31.5 (15.3–40.0) | 35.3 (21.7–49.6) | 0.01 |
| Platelets before TPL (103/μl) | 83 (42–185) | 92 (27–285) | 0.32 |
| MELD (corrected) | 23 (6–31) | 17 (7–33) | 0.014 |
| MELD (uncorrected) | 21 (6–31) | 12 (6–32) | 0.13 |
| CHILD (A/B/C in %) | 23.1/30.8/46.1 | 35.4/41.8/22.8 | 0.20 |
| Diabetes mellitus (%) | 33.3% | 16.8% | 0.12 |
| Admission from (Home/ward/ICU in %) | 66.6/13.3/20.0 | 88.2/4.7/7.1 | 0.09 |
| ASA class (II/III/IV in %) | 6.7/53.3/40.0 | 11.8/61.2/27.0 | 0.55 |
| Operating time (min) | 390 (275–705) | 355 (240–570) | 0.11 |
| Estimated intraoperative Blood loss (ml) | 3000 (500–15000) | 1000 (300–10000) | 0.05 |
| Marginal grafts (%) | 46.7 | 35.3 | 0.40 |
| Transfusion of – RBC (Unit) | 2 (0–47) | 3 (0–23) | 0.36 |
| - FFP (Unit) | 12 (0–77) | 12 (0–50) | 0.62 |
| - Platelets (Units) | 1 (0–12) | 0 (0–18) | 0.37 |
| - Fibrinogen (g) | 2 (0–22) | 0 (0–12) | 0.08 |
| Length of stay in ICU (days) | 8 (3–54) | 4 (2–31) | 0.0003 |
| Readmissions (%) | 33.3 | 16.5 | 0.006 |
| Incidence of Sepsis (%) | 40.0 | 3.5 | 0.0001 |
| Incidence of Respiratory Failure (w. reintubation) (%) | 26.7 | 5.9 | 0.009 |
| Reoperations (%) | 40.0 | 10.6 | 0.001 |
| Bilirubin peak (μmol/l) | 157 (65–475) | 87 (13–453) | 0.003 |
| ALT peak (U/l) | 1625 (346–5147) | 870 (133–7249) | 0.02 |
| AST peak (U/l) | 1926 (389–10740) | 1047 (114–13560) | 0.02 |
Data expressed as median (range) or number of patients (percentage), TPL indicates transplantation, MELD model for end stage liver disease and ICU intensive care unit, respectively.
Patients with impaired baseline creatinine clearance (< 60 ml/min)
| Gender (m/f) | 10/0 | 20/5 | 0.12 |
| Age (yrs.) | 56 (36–68) | 49 (23–70) | 0.18 |
| BMI (kg/m2) | 26.7 (23.2–31.8) | 23.7 (18.7–33.0) | 0.03 |
| Hematocrit before TPL (%) | 26.8 (18.4–38.3) | 28.2 (21.6–40.7) | 0.56 |
| Platelets before TPL (103/μl) | 51 (40–158) | 83 (22–253) | 0.97 |
| MELD (corrected) | 22 (19–33) | 23 (11–36) | 0.55 |
| MELD (uncorrected) | 21 (19–28) | 16 (6–36) | 0.19 |
| CHILD (A/B/C in %) | 0/0/100 | 15/20/65 | 0.15 |
| Diabetes mellitus (%) | 10.0% | 8.0% | 0.85 |
| Admission from (Home/ward/ICU in %) | 30.0/40.0/30.0 | 60.0/28.0/12.0 | 0.23 |
| ASA class (II/III/IV in %) | 0/30.0/70.0 | 8.0/28.0/64.0 | 0.65 |
| Operating time (min) | 362 (250–660) | 367 (260–480) | 0.50 |
| Estimated intraoperative Blood loss (ml) | 3000 (200–10000) | 1500 (500–8000) | 0.31 |
| Marginal grafts (%) | 60 | 36 | 0.19 |
| Transfusion of - RBC (Unit) | 13 (2–39) | 7 (0–20) | 0.02 |
| - FFP (Unit) | 10 (0–55) | 14 (0–36) | 0.85 |
| - Platelets (Units) | 3 (0–6) | 1 (0–12) | 0.22 |
| - Fibrinogen (g) | 7 (0–22) | 2 (0–20) | 0.04 |
| Length of stay in ICU (days) | 10 (5–94) | 4 (2–18) | 0.0002 |
| Readmissions (%) | 60.0 | 16.0 | 0.03 |
| Incidence of Sepsis (%) | 20.0 | 0 | 0.02 |
| Incidence of Respiratory Failure (w. reintubation) (%) | 30.0 | 4.0 | 0.04 |
| Reoperations (%) | 50.0 | 12.0 | 0.04 |
| Bilirubin peak (μmol/l) | 128 (57–535) | 119(14–568) | 0.42 |
| ALT peak (U/l) | 656 (133–8492) | 632 (95–4727) | 0.91 |
| AST peak (U/l) | 922 (183–13805) | 979 (119–4305) | 0.68 |
Data expressed as median (range) or number of patients (percentage), TPL indicates transplantation, MELD model for end stage liver disease and ICU intensive care unit, respectively.